Cancidas (can-SIGH-das, caspofungin), a new IV antifungal

March 2001

You'll hear more about Cancidas (can-SIGH-das, caspofungin), a new IV antifungal...from Merck.

Cancidas is the first of a new class...the echinocandins. It works by inhibiting the formation of the fungal cell wall.

Cancidas is approved for treating invasive aspergillosis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

infections might play a significant role in many chronic diseases
Gastroenterology Nexium, a follow-up to their Prilosec proton pump inhibitor
Women's Health NSAIDs during pregnancy
acetylcysteine (Mucomyst) can help prevent renal damage from IV contrast dyes
Antipsychotics Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia
Infectious Diseases if the Lyme vaccine triggers severe arthritis in some patients
Infectious Diseases Cancidas (can-SIGH-das, caspofungin), a new IV antifungal
Supplements new concerns about the safety of kava
potential for mix-ups between Depakote ER and the original Depakote (divalproex) tablets
Provigil (modafinil) for depression
Hepatitis C Trental (pentoxifylline) is beneficial for patients with severe alcoholic hepatitis
garlic supplements can interact with HIV protease inhibitors
new thinking on when to start HIV therapy
Vaccines parents' misconceptions about immunizations